RapidAI

RapidAI is a medical-imaging AI company specializing in stroke and neurovascular care. Spun out of Stanford's iSchemaView, its Rapid platform analyzes CT and MRI brain imaging to detect large-vessel occlusions (LVOs), quantify CT perfusion (identifying salvageable brain tissue), and triage suspected strokes — automatically routing cases and alerting the stroke team so that time-critical treatment can begin faster. Time is brain in stroke care, and RapidAI's tools are widely embedded in comprehensive stroke networks worldwide.

RapidAI is the principal head-to-head competitor to catalogued Viz.ai, and the two define the stroke-imaging AI category. A 2025-26 study (DUEL) reported higher LVO-detection sensitivity for RapidAI in a large head-to-head, though as with any vendor-associated comparison the results should be read alongside independent evidence. Beyond stroke, RapidAI has extended into aneurysm and pulmonary-embolism workflows. The core value proposition is speed and coordination — getting the right patient to the right intervention faster — and the core caveats are the usual ones for triage AI: it accelerates and prioritizes the human read rather than replacing it.